Work

P-003: A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (trial in progress)

Year: 2022

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(22)00333-0

Authors: Shaji Kumar, Prashant Kapoor, Alvaro Alencar, Guru Subramanian Guru Murthy, Marc Hoffmann, John Pagel, Vishalkumar Patel, James Pauff, Pier Luigi Zinzani, Steven Le Gouill, Anthony R. Mato, Wojciech Jurczak, Lindsey E. Roeker

Language: English

Topic: Cell death mechanisms and regulation

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4293232292

Cites:

Cited by:

Related to: 10